Mn Superoxide Dismutase

Recombinant ID:

2446

Request Datasheet

Gene of Interest

Gene Synonyms:

SOD2

Protein Names:

Superoxide dismutase [Mn], mitochondrial (EC 1.15.1.1)

Accession Data

Organism:

Homo sapiens (Human)

Mass (kDa):

24750

Length (aa):

222

Sequence:

MLSRAVCGTSRQLAPVLGYLGSRQKHSLPDLPYDYGALEPHINAQIMQLHHSKHHAAYVNNLNVTEEKYQEALAKGDVTAQIALQPALKFNGGGHINHSIFWTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVTERYMACKK

Proteomics (Proteome ID):

Superoxide dismutase [Mn], mitochondrial (EC 1.15.1.1)

Proteomics (Chromosome):

UP000005640

Mass Spectrometry:

N/A

Function [CC]:

Destroys superoxide anion radicals which are normally produced within the cells and which are toxic to biological systems. {ECO:0000269|PubMed:10334867}.

Metal Binding:

METAL 50 50 Manganese.; METAL 98 98 Manganese.; METAL 183 183 Manganese.; METAL 187 187 Manganese.

Site:

N/A

Tissue Specificity:

N/A

Disease:

Microvascular complications of diabetes 6 (MVCD6) [MIM:612634]: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis. {ECO:0000269|PubMed:12624725, ECO:0000269|PubMed:18989629}. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.

Mutagenesis:

MUTAGEN 58 58 Y->A,H,N,V,F: Reduced enzyme activity. {ECO:0000269|PubMed:10334867}.; MUTAGEN 58 58 Y->F: Loss of nitration. Enhanced dityrosine formation on peroxynitrite treatment. {ECO:0000269|PubMed:10334867}.

Reagent Data

Name:

Superoxide dismutase [Mn], mitochondrial (EC 1.15.1.1)

Class:

Subcategory:

Recombinant

Molecular Weight:

Source:

Species:

Human

Amino Acid Sequence:

MGSSHHHHHH SSGLVPRGSH MKHSLPDLPY DYGALEPHIN AQIMQLHHSK HHAAYVNNLN VTEEKYQEAL AKGDVTAQIA LQPALKFNGG GHINHSIFWT NLSPNGGGEP KGELLEAIKR DFGSFDKFKE KLTAASVGVQ GSGWGWLGFN KERGHLQIAA CPNQDPLQGT TGLIPLLGID VWEHAYYLQY KNVRPDYLKA IWNVINWENV TERYMACKK

Tag:

Format:

Solution

Formulation:

Sterile-filtered colorless solution

Formulation Concentration:

1mg/ml

Buffer Volume:

20mM

Buffer Solution:

Tris-HCl

pH:

8

Stabilizers

NaCl:

Null

Metal Chelating Agents

EDTA:

Null

Purity:

> 95%

Determined:

SDS-PAGE

Stained:

Inquire

Validated:

Inquire

Sample Handling

Storage:

4°C

Stability:

This bioreagent is stable at 4°C (short-term) and -70°C(long-term). After reconstitution, sample may be stored at 4°C for 2-7 days and below -18°C for future use.

Preparation:

Reconstitute in sterile distilled H2O to no less than 100ug/ml; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.